NSE filing, NSE: MUKKA. Summary written from the filing by ALFA Finder's alert engine.
Mukka Proteins Ltd: key numbers
- Share price
- ₹24.19
- Market cap
- ₹725.7 Cr
- Revenue (annual)
- ₹1,449 Cr
- Net profit (annual)
- ₹52.06 Cr
- P/E (TTM)
- 10.5×Sector 26.2×
- Promoter holding
- 73.33%+0.00% QoQ
- FII holding
- 1.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mukka Proteins Ltd
All →Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Mukka Proteins Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Mukka Proteins Production Started
Mukka Proteins Limited announced its subsidiary, United Gulf Fishery Products LLC, has commenced commercial production in Oman. The facility will produce fish meal and oil.
Mukka Proteins Debt & Borrowing: ₹73.58 Cr
Mukka Proteins Limited approved a corporate guarantee and SBLC worth Rs. 73.58 Crore for its subsidiary in Oman. The security supports credit facilities from HDFC Bank.
- Value
- ₹73.58 Cr
Mukka Proteins Credit Rating
CARE Ratings has reaffirmed the credit ratings of Mukka Proteins Ltd at CARE BBB-; Stable / CARE A3.
Mukka Proteins Credit Rating
CARE Ratings reaffirmed the credit ratings for Mukka Proteins Ltd's bank facilities totaling ₹495 Crore and revised the outlook from Negative to Stable.
- Value
- ₹495.0 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
KFIN Technologies Regulatory Approval
KFin Technologies' Thai subsidiary received a Foreign Business License from Thailand's Ministry of Commerce. The license enables the subsidiary to conduct permitted business activities under local law.